文献速递肝病消化道肿瘤与早癌

抗病毒治疗期间丙氨酸氨基转移酶早期正常化与慢性乙型肝炎患者肝细胞癌风险降低独立相关

Earlier Alanine Aminotransferase Normalization During Antiviral Treatment Is Independently Associated With Lower Risk of Hepatocellular Carcinoma in Chronic Hepatitis B.
PubMed 文献 · Am J Gastroenterol · 2020-01-01

该研究分析了4639例接受恩替卡韦或替诺福韦治疗的慢性乙型肝炎患者,发现治疗期间丙氨酸氨基转移酶(ALT)正常化与肝细胞癌(HCC)风险显著降低独立相关,且ALT正常化越早,HCC风险越低,此关联不受基线脂肪肝或肝硬化及治疗期间病毒学应答影响。

要点

  • ALT正常化与HCC风险降低独立相关(AHR 0.57)。
  • ALT正常化延迟与HCC风险递增相关。
  • 早期病毒学应答或HBeAg血清清除与HCC风险无显著关联。

核心结论

  • 在恩替卡韦或替诺福韦治疗的CHB患者中,早期ALT正常化与HCC风险成比例降低独立相关,不受基线脂肪肝或肝硬化及治疗期间病毒学应答影响。

研究设计与样本

  • 研究分析了4639例开始恩替卡韦或替诺福韦治疗的CHB患者,采用landmark分析和时间依赖Cox分析。

主要发现

  • 中位治疗5.6年期间,509例(11.0%)患者发生HCC。
  • ALT正常化在1年时为65.6%,2年时为81.9%,与显著降低的HCC风险相关(P < 0.001;AHR 0.57)。
  • 与6个月内ALT正常化相比,6-12、12-24和>24个月延迟正常化的HCC风险递增(AHR分别为1.40、1.74和2.45;P < 0.001)。
  • 早期病毒学应答(AHR 0.93;P = 0.53)或早期HBeAg血清清除(AHR 0.91;P = 0.31)与HCC风险降低无显著关联。

关键数值与推荐

  • ALT正常定义为≤35 U/L(男性)和≤25 U/L(女性)。
  • 病毒学应答定义为血清HBV DNA <15 IU/mL。

临床怎么用

  • 对于接受恩替卡韦或替诺福韦治疗的CHB患者,应关注ALT正常化的时间,早期正常化与更低HCC风险相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: It was suggested that normalization of serum alanine aminotransferase (ALT) levels at 1 year of antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B (CHB). However, it remains unclear whether earlier ALT normalization is associated with lower hepatocellular carcinoma (HCC) risk, independent of fatty liver or cirrhosis and on-treatment virological response (VR), in patients with CHB. METHODS: We analyzed 4,639 patients with CHB who initiated treatment with entecavir or tenofovir using landmark analysis and time-dependent Cox analysis. We defined normal ALT as ≤35 U/L (men) and ≤25 U/L (women) and VR as serum hepatitis B virus DNA <15 IU/mL. RESULTS: During a median 5.6 years of treatment, 509 (11.0%) patients developed HCC. ALT normalization occurred in 65.6% at 1 year and 81.9% at 2 years and was associated with a significantly lower HCC risk in landmark (P < 0.001) and time-dependent Cox analyses (adjusted hazard ratio [AHR] 0.57; P < 0.001). Compared with ALT normalization within 6 months, delayed ALT normalization at 6-12, 12-24, and >24 months was associated with incrementally increasing HCC risk (AHR 1.40, 1.74, and 2.45, respectively; P < 0.001), regardless of fatty liver or cirrhosis at baseline and VR during treatment. By contrast, neither earlier VR (AHR 0.93; P = 0.53) nor earlier hepatitis B e antigen seroclearance (AHR 0.91; P = 0.31) was associated with a significantly lower HCC risk. DISCUSSION: In patients with CHB treated with entecavir or tenofovir, earlier ALT normalization was independently associated with proportionally lower HCC risk, regardless of fatty liver or cirrhosis at baseline and on-treatment VR.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Choi J, Kim GA, Han S, et al. Earlier Alanine Aminotransferase Normalization During Antiviral Treatment Is Independently Associated With Lower Risk of Hepatocellular Carcinoma in Chronic Hepatitis B. Am J Gastroenterol. 2020. PMID: 31895708. doi:10.14309/ajg.0000000000000490

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。